# Pharmacogenomics in Hypertension: Signal, Evidence, Application

Use pharmacogenomics only for a defined drug decision with established guidance; exposure predictions never replace measured BP, pulse, and tolerability.

![Infographic: Pharmacogenomics in Hypertension: Signal, Evidence, Application](https://urinenephrology.org/visual-reference/images/bp-pharmacogenomics.png?v=20261003c)

## Ask whether this result changes a drug

A variant can affect exposure without proving improved clinical outcomes from testing. Identify the exact medicine, gene, phenotype, and decision: starting dose, titration, adverse-effect monitoring, or alternative. A broad “hypertension gene” score is not a validated prescription.

## A concrete actionable example

CPIC 2024 links CYP2D6 poor metabolism to greater metoprolol exposure and heart-rate reduction. Start at the lowest recommended dose, titrate carefully, and monitor more closely for bradycardia; another beta blocker may be appropriate. The clinical indication still determines the treatment goal.

## Know the no-recommendation boundary

CPIC does not provide genotype-guided recommendations for every beta blocker or for all receptor/signaling variants studied. Normal/intermediate CYP2D6 metabolism generally uses standard metoprolol starting guidance. Insufficient evidence is not permission to invent a percentage dose correction.

## Inhibitors can mimic poor metabolism

Paroxetine or fluoxetine can inhibit CYP2D6 and increase metoprolol exposure regardless of an apparently normal genotype. Review new medicines when pulse/BP falls. Genetics and drug interactions describe related but distinct causes of reduced functional metabolism.

## Read the evidence before ordering

Check whether the guideline tells how to use an existing result or actually recommends testing. Review variant coverage, ancestry representation, phenotype translation, cost, and whether a result will change management. Explain limitations before obtaining a broad panel.

## Let the patient’s response decide

Continue standardized BP/pulse, symptom, and relevant laboratory monitoring after any genotype-informed choice. A stable tolerated regimen does not automatically need changing because a genotype arrives. New bradycardia, syncope, or hypotension requires clinical review rather than reliance on the predicted phenotype.

## Supporting evidence

- [Clinical evidence and guidance](https://files.cpicpgx.org/data/guideline/publication/beta_blockers/2024/38951961.pdf)
- [PubMed 38951961](https://pubmed.ncbi.nlm.nih.gov/38951961/)

## Source lessons

- [pharmacogenomics](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/pharmacogenomics.html)

Read alongside the full lessons; the findings and decisions shown here require the stated clinical context.